Health

NHS Extends Palantir Data Contract Until 2029

NHS Extends Palantir Data Contract Until 2029
Table of Contents
  1. Concerns Over the Partnership
  2. Government and Industry Perspectives
  3. Palantir’s Response

The UK government has confirmed it will retain its major NHS data contract with the US technology firm Palantir until 2029. While the government opted not to trigger an early release clause that would have allowed the agreement to end next year, it plans to launch a procurement process next summer to invite British companies to bid for the contract once the current term expires.

Concerns Over the Partnership

The £330 million deal, which commenced in 2024, was originally intended to run until 2031 to assist in managing hospital waiting lists across England. However, the partnership has faced significant criticism. A Commons Committee previously urged the government to sever ties with the company, suggesting the appointment of a firm more aligned with UK values. Furthermore, Palantir has been the subject of regular protests regarding its technology’s use in US immigration enforcement and by the Israeli military in the Gaza conflict.

Some Labour MPs have expressed strong disappointment with the government’s decision. Former shadow chancellor John McDonnell described the contract as an “albatross” around the neck of the NHS and accused the company of “human rights abuses.” Liberal Democrat health spokeswoman Helen Morgan also criticized the firm, citing its human rights record and the political affiliations of its leadership.

Government and Industry Perspectives

Health minister James Frith defended the decision, stating that the government’s focus is not on the political activities of a supplier’s executives or their other global clients. The government emphasized that it intends to encourage UK-based firms to tender for future contracts to prevent over-reliance on a single supplier.

Despite this, some officials believe the transition timeline is too slow. Dame Chi Onwurah, Labour MP for Newcastle upon Tyne Central and West, argued that the government must act with urgency to secure domestic alternatives rather than waiting two years to reduce dependency. The British Medical Association (BMA) noted that while it is pleased the government is acknowledging concerns regarding Palantir, it remains frustrated by the delay in transitioning to a different provider.

Palantir’s Response

Palantir UK maintains that continuing the program is the correct course of action, noting that the current initiative is exceeding its performance targets. Tom Watson, senior vice-president of Palantir UK, stated that the company is proud of its contributions, which include helping to increase the number of operations performed, accelerating patient discharges, and reducing wait times for cancer diagnoses.

You May Also Like

Leave a Comment

Your email address will not be published. Required fields are marked *